How Sickness Became A Business
July 20, 2026
For decades, the leading causes of chronic disease have been well understood. The mechanisms of cancer have been mapped at the molecular level. The chemicals added to products have been identified. The links between ultra-processed food and obesity have been measured. The solutions have been documented. Yet the diseases persist, the death tolls continue and the industries most responsible grow larger and more profitable every year.
A great example is the tobacco industry. Commercial cigarettes are not simply dried tobacco leaves rolled in natural paper. They are highly engineered products with over 100 chemical additives, designed by scientists who totally understand what they are creating. Since exact formulas are often proprietary and kept secret, what is known comes largely from documents released through litigation and partial regulatory disclosures.
- Sugars (sucrose, glucose, high fructose corn syrup) are added to tobacco to make a sweet, milder smoke that can be inhaled deeply.
- Ammonia compounds are added so nicotine is fast-absorbing and more addictive.
- Menthol is used to reduce throat irritation and coughing, suppressing the body's innate protective response.
- Potassium nitrate is added so cigarettes burn between puffs, generating nitrosamines that are among the most potent carcinogens.
Radioactive polonium, absorbed by tobacco plants from phosphate fertilizers, was identified as early as the 1960s. The industry studied it, considered filtering it out and quietly shelved the research to avoid public relations consequences. These weren't oversights. They were decisions.
In the 1980s, when smoking began to wane, tobacco companies diversified. They acquired General Foods, Kraft and Nabisco brands, and the accumulated know-how of engineering addictive products didn't go to waste. Food scientists working for these companies refined the precise formula of sugar, salt and fat to maximize the urge to keep eating while suppressing natural satiety signals. Artificial emulsifiers, preservatives and flavor compounds were added in combinations that prioritized taste and shelf life over long term biological effects.
The results are measurable. Obesity rates in the United States have tripled since the 1970s. Type 2 diabetes, once almost unheard of in children, is now a pediatric health crisis. Colorectal cancer rates are rising sharply in young adults in patterns that track closely with ultra-processed food consumption. The United States spends more on healthcare per capita than any nation on earth, while life expectancy and good health have rapidly declined.
The strategy used to be: Create the problem - profit from the solution. But not anymore. The management of illness is what generates the big bucks. The global cancer treatment market exceeds $200 billion annually. The diabetes drug market exceeds $60 billion. Cardiovascular, autoimmune and depression meds each represent a multi-billion dollar revenue stream, generated by conditions that in many cases have documented preventions that receive a mere fraction of the research funding and clinical attention that pharmaceutical management does.
The reason is structural, financial and a bit sinister. Drug development is expensive and funded by companies that recover their investment through patent-protected sales. A patented drug generating revenue for twenty years represents a return on investment. An inexpensive, off-patent drug for the treatment of cancer represents an expenditure with no return. A nutritional plan that prevents diabetes represents no pharmaceutical revenue at all. The research pipeline reflects these incentives with disturbing accurancy - it is systematically skewed toward patentable, costly, long-term treatments and away from prevention, cures and simple medicines. This isn't just speculation. Researchers, health economists and physicians state it plainly. The incentives are visible, the outcomes are measurable and the pattern has been consistent for decades.
When promising signs emerged in oncology research regarding antiparasitic drugs, like mebendazole, fenbendazole, ivermectin and hydroxychloroquine, showing anticancer activity in lab tests and documented case reports, large-scale clinical trials didn't follow. Not because the science was dismissed, but because these drugs are off-patent, cheap and generically available. No company stood to profit from proving they worked. The trials that would answer the question remain underfunded, while patented, costly treatments receive extensive industry backing.
Pharmaceutical companies have suppressed unfavorable trial results in cases that cost billions of dollars in legal settlements - costs that were still lower than the revenue the concealment protected. They have spent hundreds of millions annually lobbying the legislators who set drug pricing policy and research funding priorities. They have moved executives through revolving doors into regulatory agencies and back, creating relationships that compromise genuine accountability.
Cancer itself, a most feared disease, is now understood at the molecular level with enough precision to design drugs targeting specific mutations in specific genes. The knowledge exists. What has not existed for a very long time, is the financial incentive to apply that knowledge toward keeping people healthy, rather than managing their sickness for profitably. A patient cured is a customer lost. A patient chronically managed is a customer retained. This is not healthcare. It's a financial business strategy for lucrative gains.
Everything discussed here are documented facts, drawn from court records, released internal documents, lobbying disclosures, public records and published research. None of this is hidden. It is simply rarely compiled into a single coherent picture for all to see and understand.
The question that remains isn't whether these industries prioritize profit over lives. The evidence on that point is sufficient. The question is, what are we going to do about it?